GSK Argues Its Strategy Is Delivering As Still More Cuts Are Made, Including in R&D
This article was originally published in The Pink Sheet Daily
CEO Witty suggests group has emerged from worst of patent storm with an upbeat forecast for 2010 and promises of further cost-cutting.
You may also be interested in...
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.
Specialty Pharma Dominates Epilepsy Market, But Does It Have Resources To Develop Disease-Modifying Agents?
Upsher-Smith’s recent acquisition of research boutique Proximagen highlights the dynamics of the market: specialty pharma extending dominance and introducing new agents to the market, while most early R&D activity originates at small firms. But it may be difficult for this combination of players to bring forth the game-changing therapies that are needed, given the technical challenges of the disease space.
GlaxoSmithKline is to invest £500 million in new U.K. manufacturing facilities in Ulverston, Montrose and Irvine, creating 1,000 jobs in the process.